Sara joined Insmed in January 2020, bringing more than 15 years of operational and financial leadership in the life sciences industry. Sara has extensive experience leading public biotech companies as CFO. Prior to joining Insmed, she served as the Chief Financial Officer, Chief Operating Officer, and Corporate Secretary at OncoSec Medical and as the Chief Financial Officer, Secretary, Treasurer, and Executive Vice President at Advaxis, Inc. In these roles, Sara raised over $300 million in the capital marketplace and licensing deals. She also established strong financial controls, streamlined business operations, and was responsible for the overall leadership and management of operations, including corporate finance, investor relations, business development, IT, facilities, legal, and human resources. At Eli Lilly & Company, Sara was a Six Sigma Champion and Black Belt. Prior to her Six Sigma role, she was the Director of Finance at Eli Lilly and ImClone, and before that she was a financial analyst at Johnson & Johnson. In 2016, NJBiz named Sara CFO of the Year – Healthcare Organization and Forty under 40. Sara is a graduate of Johnson & Johnson’s Financial Leadership Development Program. She holds a BS in Finance from The College of New Jersey and an M.B.A. from Rider University. Sara is a member of the board of directors of scPharmaceuticals Inc. (Nasdaq: SCPH) and Xilio Therapeutics, Inc.